Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriele Niedermann

Showing results (71-80 of 74) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 74 results.
Nature Communications|July 8, 2026
SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8<sup>+</sup> T cell immunity against bulky tumors via an IFN-I/NK/DC axisRen Luo, Min Yu, Kai Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer PatientsXiaojuan Zhou, Laiyan Zhou, Zhuoran Yao, et al.
Cell|September 19, 2017
Mitochondrial Priming by CD28Ramon I Klein Geltink, David O'Sullivan, Mauro Corrado, et al.
Science Translational Medicine|February 23, 2018
Oncogenic JAK2<sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasmsAlessandro Prestipino, Alica J Emhardt, Konrad Aumann, et al.
Pageof 8

Showing results (71-80 of 74) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 74 results.
Nature Communications|July 8, 2026
SBRT embedded in low-dose RT plus αPD-1 (immuno-EclipseRT, iERT) elicits CD8<sup>+</sup> T cell immunity against bulky tumors via an IFN-I/NK/DC axisRen Luo, Min Yu, Kai Kang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2023
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non-Small Cell Lung Cancer PatientsXiaojuan Zhou, Laiyan Zhou, Zhuoran Yao, et al.
Cell|September 19, 2017
Mitochondrial Priming by CD28Ramon I Klein Geltink, David O'Sullivan, Mauro Corrado, et al.
Science Translational Medicine|February 23, 2018
Oncogenic JAK2<sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasmsAlessandro Prestipino, Alica J Emhardt, Konrad Aumann, et al.
Pageof 8